Femoxetine

Source: Wikipedia, the free encyclopedia.
Femoxetine
Clinical data
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
  • In general: uncontrolled
Pharmacokinetic data
Elimination half-life7–27 hours
Identifiers
  • (3R,4S)-3-[(4-methoxyphenoxy)methyl]-1-methyl-4-phenyl-piperidine
JSmol)
  • O(c1ccc(OC)cc1)C[C@@H]3[C@@H](c2ccccc2)CCN(C)C3
  • InChI=1S/C20H25NO2/c1-21-13-12-20(16-6-4-3-5-7-16)17(14-21)15-23-19-10-8-18(22-2)9-11-19/h3-11,17,20H,12-15H2,1-2H3/t17-,20-/m1/s1 checkY
  • Key:OJSFTALXCYKKFQ-YLJYHZDGSA-N checkY
  (verify)

Femoxetine (

INN; tentative brand name Malexil; developmental code name FG-4963) is a drug related to paroxetine that was being developed as an antidepressant by Danish pharmaceutical company Ferrosan in 1975 before acquisition of the company by Novo Nordisk. It acts as a selective serotonin reuptake inhibitor (SSRI). Development was halted to focus attention on paroxetine
instead, as femoxetine could not be administered as a daily pill.

Both femoxetine and paroxetine were invented in the 1970s. Jørgen Anders Christensen's name is on the patents

After Ferrosan's acquisition, femoxetine died from neglect.[4]

In a separate patent, Ferrosan stated that Femoxetine could be used as an appetite suppressant,[5] using ten times the dosage than for paroxetine, 300 - 400mg daily.

Femoxetine has the same stereochemical properties as

Nocaine, another agent with a similar structure claimed to have been synthesized using arecoline as the starting alkaloid.[citation needed
]

Analogs

  1. Addition of the para-fluoro atom results in a different compound that is a hybrid of femoxetine & paroxetine named FG 7080,[6] which has a separate patent.[7] According to the patent tables, incorporation of the fluorine atom potentiated the 5-HT affinity considerably.
  2. Pfizer made some similar analogs[8] E.g. a Viloxazine type of catechol ether is used, but 4-phenyl instead of based on a morpholine ring.
  3. NNC-63-0780.
    ORL1 instead of SERT
    .
  • NNC 09-0026

See also

References